The European Commission decided on Tuesday 6 September to prohibit the acquisition of GRAIL by Illumina under the EU Merger Regulation.
The merger would have stifled innovation and reduced choice in the emerging market for blood-based early cancer detection tests.Illumina has not proposed sufficient remedies to address these concerns (see EUROPE B12996A13).
The European Commission opened an in-depth investigation on 22 July to assess Illumina’s proposed acquisition of GRAIL (see EUROPE...